Full Press Release Details
Pharmaceuticals Announces Publication of Research Article on its Oral Insulin
Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
data shows ORMD-0801 resulted in glucose and c-peptide reduction
Israel - May 26, 2010- Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB)
(http://www.oramed.com), a developer of alternative drug delivery systems,
announced today that the paper entitled, "Open-label study to assess the safety
and pharmacodynamics of five oral insulin formulations in healthy subjects,"
authored by Dr. Roy Eldor, Dr. Miriam Kidron and Dr. Ehud Arbit, was accepted
and published in the Diabetes, Obesity and Metabolism (DOM)
of our data in a prestigious journal such as DOM lends further credence to the
importance of oral insulin as a potential drug in the management of diabetes.
The data published on formulation optimization is an important milestone in the
development of ORMD-0801, and provides the continued evidence of clinical safety
and the foundation for the proof of concept study for our proprietary oral drug
delivery platform," said Dr. Miriam Kidron, Chief Officer of
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking to
revolutionize the treatment of diabetes through its patented flagship product,
an orally ingestible insulin capsule currently in Phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years of research
performed by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
information, please visit http://www.oramed.com.
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
and Investor Relation Contacts:
Pharmaceuticals Inc.
972-54-334-4318Email: tara@oramed.com